Jones Financial Companies Lllp Buys New Position in Twist Bioscience Corporation $TWST

Key Points

• Jones Financial Companies Lllp acquired approximately 224,605 shares of Twist Bioscience Corporation, valued at about $9.49 million, increasing its stake to around 0.37%.
• Analysts have a consensus target price of $49.40 for Twist Bioscience, with most giving the stock a "Moderate Buy" rating.
• The company reported quarterly earnings of ($0.47) EPS, surpassing analysts' expectations by $0.07, and generated $96.06 million in revenue.

Jones Financial Companies Lllp acquired a new stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 224,605 shares of the company's stock, valued at approximately $9,492,000. Jones Financial Companies Lllp owned about 0.37% of Twist Bioscience at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of TWST. Versant Capital Management Inc lifted its stake in shares of Twist Bioscience by 547.2% in the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after purchasing an additional 580 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after acquiring an additional 303 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Twist Bioscience during the 4th quarter worth approximately $58,000. Bayforest Capital Ltd lifted its stake in shares of Twist Bioscience by 49.3% during the 1st quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock worth $191,000 after acquiring an additional 1,604 shares during the last quarter. Finally, Pallas Capital Advisors LLC bought a new stake in shares of Twist Bioscience during the 1st quarter worth approximately $201,000.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 2,265 shares of the business's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $25.76, for a total value of $58,346.40. Following the completion of the transaction, the chief executive officer directly owned 634,740 shares of the company's stock, valued at approximately $16,350,902.40. The trade was a 0.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Adam Laponis sold 2,449 shares of the business's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total value of $93,429.35. Following the completion of the transaction, the chief financial officer directly owned 103,569 shares of the company's stock, valued at approximately $3,951,157.35. The trade was a 2.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,911 shares of company stock valued at $288,159. Corporate insiders own 3.01% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Evercore ISI set a $46.00 price target on Twist Bioscience in a research note on Monday, August 4th. Cowen reissued a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Twist Bioscience has a consensus rating of "Moderate Buy" and an average target price of $49.40.

Twist Bioscience Stock Down 1.2%

NASDAQ TWST traded down $0.30 on Friday, reaching $25.31. 1,502,508 shares of the stock traded hands, compared to its average volume of 1,213,971. The company has a market cap of $1.53 billion, a price-to-earnings ratio of -17.46 and a beta of 2.31. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. Twist Bioscience Corporation has a 12 month low of $24.07 and a 12 month high of $55.33. The company has a fifty day moving average price of $30.77 and a 200-day moving average price of $34.37.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.07. The firm had revenue of $96.06 million during the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.